Institutional members access full text with Ovid®

Share this article on:

The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell transplantation

Ljungman, Per

doi: 10.1097/MOH.0000000000000085
HEMATOPOIETIC STEM CELL TRANSPLANTATION: Edited by Andrea Bacigalupo

Purpose of review The aim of this review is to discuss recent developments regarding the impact of cytomegalovirus (CMV) serological status of hematopoietic stem cell transplantation recipients and their donors on transplant outcome.

Recent findings CMV seropositivity of the recipient is still a negative factor for transplant outcome. The use of a CMV seropositive donor has a negative impact on survival in patients receiving unrelated but not human leukocyte antigen-identical sibling grafts. In CMV seropositive patients, the donor serological status influences outcome in patients receiving unrelated donor grafts after myeloablative but not reduced-intensity conditioning. Early CMV replication reduces the risk for leukemia relapse but does not improve survival. The use of leukocyte depleted blood products is sufficient to prevent primary CMV infection.

Summary Despite major advances in management of CMV infections, CMV serologic status remains an important risk factor for transplant-related complications and mortality after allogeneic hematopoietic stem cell transplantation.

Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Department of Hematology, Karolinska University Hospital, Stockholm, Sweden

Correspondence to Per Ljungman, MD, PhD, Department of Hematology, M54, Karolinska University Hospital, SE-14186 Stockholm, Sweden. Tel: +46 8 58582507; fax: +46 8 7748725; e-mail: Per.Ljungman@ki.se

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins